Delaware-based Incyte is now turning to AI to power through the coming decades.
Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the coming decades.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion…
L'azienda ha trasformato ricerca e intuizioni in soluzioni terapeutiche e ha ampliato ambiti clinici e capacità organizzative
Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance…
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered…
In this week’s edition of InnovationRx, we look at the opportunities and challenges of using AI to personalize healthcare and…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
